HTLV-1 uveitis (HU) is the third clinical entity to be designated as an HTLV-1-associated
disease. Although HU is considered to be the second-most frequent HTLV-1-associated …

Following viral infection, the innate immune system senses viral products, such as viral
nucleic acids, to activate innate defence pathways, leading to inflammation and apoptosis …

Human T-cell leukemia virus type 1 (HTLV-1), a virus that affects 5–10 million people
globally, causes several diseases, including adult T-cell leukemia-lymphoma and HTLV-1 …

Aims: The pathophysiological mechanism (s) underlying non-alcoholic fatty liver disease
(NAFLD) have yet to be fully delineated and only a single drug, peroxisome proliferator …

Introduction Human T-lymphotropic virus type 1 (HTLV-1) is a lifelong persistent retrovirus
associated with numerous systemic and ocular diseases, presenting significant clinical …

Human T-cell lymphotropic virus type 1 (HTLV-1) was the first retrovirus identified as the
causative agent of human diseases, such as adult T-cell leukemia, HTLV-1-associated …

Introduction HTLV-1 (human T-cell lymphotropic virus type 1) is a retrovirus that infects
approximately 20 million people worldwide. Many diseases are caused by this virus …

Adalimumab (ADA) is an anti-inflammatory antibody that has FDA approval as a systemic
medication for treating noninfectious uveitis. It is also provisionally being investigated as an …

There is growing interest in evaluating the safety and therapeutic potential of existing
treatments such as tocilizumab (TCZ), an IL-6 receptor antagonist used to treat inflammatory …

Objective To describe the clinical features at presentation, delivered treatment and follow-up
of a case series of human T-cell lymphotropic virus type 1 (HTLV-1) associated intermediate …